Comparative analysis of novel and conventional Hsp90 inhibitors on HIF activity and angiogenic potential in clear cell renal cell carcinoma: Implications for clinical evaluation

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Bohonowych, Jessica E S ^a   Peng, Shuping ^b   Gopal, Udhayakumar ^a   Hance, Michael W ^a   Wing, Shane B ^a   Argraves, Kelley M ^a   Lundgren, Karen ^c   Isaacs, Jennifer S ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b CENTRAL SOUTH UNIVERSITY   (China)

^c BIOGEN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EC 154; HYPOXIA INDUCIBLE FACTOR; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 2; ISOPROTEIN; PANOBINOSTAT; TANESPIMYCIN; UNCLASSIFIED DRUG; UROKINASE; VASCULOTROPIN; HEAT SHOCK PROTEIN 90; HYDROXAMIC ACID; LUCIFERASE; TUMOR PROTEIN; VASCULOTROPIN A;

ANTIANGIOGENIC ACTIVITY; ARTICLE; CELL MOTILITY; CLEAR CELL CARCINOMA; CLINICAL EVALUATION; COMPARATIVE EFFECTIVENESS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG TARGETING; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; TUMOR VASCULARIZATION; CELL MOTION; CELL SURVIVAL; DISEASE COURSE; DRUG ANTAGONISM; DRUG EFFECT; GENETIC TRANSCRIPTION; IMPEDANCE; KIDNEY TUMOR; METABOLISM; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; TUMOR CELL LINE; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; DISEASE PROGRESSION; ELECTRIC IMPEDANCE; HSP90 HEAT-SHOCK PROTEINS; HUMANS; HYDROXAMIC ACIDS; HYPOXIA-INDUCIBLE FACTOR 1; KIDNEY NEOPLASMS; LUCIFERASES; NEOPLASM PROTEINS; REAL-TIME POLYMERASE CHAIN REACTION; TRANSCRIPTION, GENETIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 83455213667     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-520     Document Type: Article

References (98)

1. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003, 3:721-732. 10.1038/nrc1187, 13130303.
2. Semenza GL. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 2009,
3. Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA 1995, 92:5510-5514. 10.1073/pnas.92.12.5510, 41725, 7539918.
4. Qing G, Simon MC. Hypoxia inducible factor-2alpha: a critical mediator of aggressive tumor phenotypes. Curr Opin Genet Dev 2009, 19:60-66. 10.1016/j.gde.2008.12.001, 3146034, 19167211.
5. Mabjeesh NJ, Amir S. Hypoxia-inducible factor (HIF) in human tumorigenesis. Histol Histopathol 2007, 22:559-572.
6. Semenza GL. Involvement of hypoxia-inducible factor 1 in human cancer. Intern Med 2002, 41:79-83. 10.2169/internalmedicine.41.79, 11868612.
7. Burkitt K, Chun SY, Dang DT, Dang LH. Targeting both HIF-1 and HIF-2 in human colon cancer cells improves tumor response to sunitinib treatment. Mol Cancer Ther 2009, 8:1148-1156. 10.1158/1535-7163.MCT-08-0944, 19435875.
8. Kaelin WG. The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma. Clin Cancer Res 2007, 13:680s-684s. 10.1158/1078-0432.CCR-06-1865, 17255293.
9. Maranchie JK, Vasselli JR, Riss J, Bonifacino JS, Linehan WM, Klausner RD. The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell 2002, 1:247-255. 10.1016/S1535-6108(02)00044-2, 12086861.
10. Kondo K, Kim WY, Lechpammer M, Kaelin WG. Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth. PLoS Biol 2003, 1:E83. 300692, 14691554.
11. Kondo K, Klco J, Nakamura E, Lechpammer M, Kaelin WG. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 2002, 1:237-246. 10.1016/S1535-6108(02)00043-0, 12086860.
12. Iliopoulos O, Levy AP, Jiang C, Kaelin WG, Goldberg MA. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci USA 1996, 93:10595-10599. 10.1073/pnas.93.20.10595, 38198, 8855223.
13. Mandriota SJ, Turner KJ, Davies DR, Murray PG, Morgan NV, Sowter HM, Wykoff CC, Maher ER, Harris AL, Ratcliffe PJ, Maxwell PH. HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron. Cancer Cell 2002, 1:459-468. 10.1016/S1535-6108(02)00071-5, 12124175.
14. Biswas S, Troy H, Leek R, Chung YL, Li JL, Raval RR, Turley H, Gatter K, Pezzella F, Griffiths JR, et al. Effects of HIF-1alpha and HIF2alpha on Growth and Metabolism of Clear-Cell Renal Cell Carcinoma 786-0 Xenografts. J Oncol 2010, 2010:757908. 2905950, 20652061.
15. Verheul HM, Salumbides B, Van Erp K, Hammers H, Qian DZ, Sanni T, Atadja P, Pili R. Combination strategy targeting the hypoxia inducible factor-1 alpha with mammalian target of rapamycin and histone deacetylase inhibitors. Clin Cancer Res 2008, 14:3589-3597. 10.1158/1078-0432.CCR-07-4306, 18519793.
16. Carroll VA, Ashcroft M. Role of hypoxia-inducible factor (HIF)-1alpha versus HIF-2alpha in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel-Lindau function: implications for targeting the HIF pathway. Cancer Res 2006, 66:6264-6270. 10.1158/0008-5472.CAN-05-2519, 16778202.
17. Toschi A, Lee E, Gadir N, Ohh M, Foster DA. Differential dependence of hypoxia-inducible factors 1{alpha} and 2{alpha} on mTORC1 and mTORC2. J Biol Chem 2008, 283:34495-34499. 10.1074/jbc.C800170200, 2596400, 18945681.
18. Rapisarda A, Uranchimeg B, Sordet O, Pommier Y, Shoemaker RH, Melillo G. Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications. Cancer Res 2004, 64:1475-1482. 10.1158/0008-5472.CAN-03-3139, 14983893.
19. Koh MY, Spivak-Kroizman T, Venturini S, Welsh S, Williams RR, Kirkpatrick DL, Powis G. Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1alpha. Mol Cancer Ther 2008, 7:90-100. 10.1158/1535-7163.MCT-07-0463, 18202012.
20. Semenza GL. Development of novel therapeutic strategies that target HIF-1. Expert Opin Ther Targets 2006, 10:267-280. 10.1517/14728222.10.2.267, 16548775.
21. Zhang H, Qian DZ, Tan YS, Lee K, Gao P, Ren YR, Rey S, Hammers H, Chang D, Pili R, et al. Digoxin and other cardiac glycosides inhibit HIF-1alpha synthesis and block tumor growth. Proc Natl Acad Sci USA 2008, 105:19579-19586. 10.1073/pnas.0809763105, 2604945, 19020076.
22. Greenberger LM, Horak ID, Filpula D, Sapra P, Westergaard M, Frydenlund HF, Albaek C, Schroder H, Orum H. A RNA antagonist of hypoxia-inducible factor-1alpha, EZN-2968, inhibits tumor cell growth. Mol Cancer Ther 2008, 7:3598-3608. 10.1158/1535-7163.MCT-08-0510, 18974394.
23. Kung AL, Zabludoff SD, France DS, Freedman SJ, Tanner EA, Vieira A, Cornell-Kennon S, Lee J, Wang B, Wang J, et al. Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway. Cancer Cell 2004, 6:33-43. 10.1016/j.ccr.2004.06.009, 15261140.
24. Minet E, Mottet D, Michel G, Roland I, Raes M, Remacle J, Michiels C. Hypoxia-induced activation of HIF-1: role of HIF-1alpha-Hsp90 interaction. FEBS Lett 1999, 460:251-256. 10.1016/S0014-5793(99)01359-9, 10544245.
25. Isaacs JS, Jung YJ, Mimnaugh EG, Martinez A, Cuttitta F, Neckers LM. Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway. J Biol Chem 2002, 277:29936-29944. 10.1074/jbc.M204733200, 12052835.
26. Mabjeesh NJ, Post DE, Willard MT, Kaur B, Van Meir EG, Simons JW, Zhong H. Geldanamycin induces degradation of hypoxia-inducible factor 1alpha protein via the proteosome pathway in prostate cancer cells. Cancer Res 2002, 62:2478-2482.
27. Katschinski DM, Le L, Schindler SG, Thomas T, Voss AK, Wenger RH. Interaction of the PAS B domain with HSP90 accelerates hypoxia-inducible factor-1alpha stabilization. Cell Physiol Biochem 2004, 14:351-360. 10.1159/000080345, 15319539.
28. Liu YV, Baek JH, Zhang H, Diez R, Cole RN, Semenza GL. RACK1 competes with HSP90 for binding to HIF-1alpha and is required for O(2)-independent and HSP90 inhibitor-induced degradation of HIF-1alpha. Mol Cell 2007, 25:207-217. 10.1016/j.molcel.2007.01.001, 2563152, 17244529.
29. Bisht KS, Bradbury CM, Mattson D, Kaushal A, Sowers A, Markovina S, Ortiz KL, Sieck LK, Isaacs JS, Brechbiel MW, et al. Geldanamycin and 17-allylamino-17-demethoxygeldanamycin potentiate the in vitro and in vivo radiation response of cervical tumor cells via the heat shock protein 90-mediated intracellular signaling and cytotoxicity. Cancer Res 2003, 63:8984-8995.
30. Hollingshead M, Alley M, Burger AM, Borgel S, Pacula-Cox C, Fiebig HH, Sausville EA. In vivo antitumor efficacy of 17-DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride), a water-soluble geldanamycin derivative. Cancer Chemother Pharmacol 2005, 56:115-125. 10.1007/s00280-004-0939-2, 15791458.
31. Sanderson S, Valenti M, Gowan S, Patterson L, Ahmad Z, Workman P, Eccles SA. Benzoquinone ansamycin heat shock protein 90 inhibitors modulate multiple functions required for tumor angiogenesis. Mol Cancer Ther 2006, 5:522-532. 10.1158/1535-7163.MCT-05-0439, 16546966.
32. Alqawi O, Moghaddas M, Singh G. Effects of geldanamycin on HIF-1alpha mediated angiogenesis and invasion in prostate cancer cells. Prostate Cancer Prostatic Dis 2006, 9:126-135. 10.1038/sj.pcan.4500852, 16432534.
33. Lang SA, Moser C, Gaumann A, Klein D, Glockzin G, Popp FC, Dahlke MH, Piso P, Schlitt HJ, Geissler EK, Stoeltzing O. Targeting heat shock protein 90 in pancreatic cancer impairs insulin-like growth factor-I receptor signaling, disrupts an interleukin-6/signal-transducer and activator of transcription 3/hypoxia-inducible factor-1alpha autocrine loop, and reduces orthotopic tumor growth. Clin Cancer Res 2007, 13:6459-6468. 10.1158/1078-0432.CCR-07-1104, 17975158.
34. Ronnen EA, Kondagunta GV, Ishill N, Sweeney SM, Deluca JK, Schwartz L, Bacik J, Motzer RJ. A phase II trial of 17-(Allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma. Invest New Drugs 2006, 24:543-546. 10.1007/s10637-006-9208-z, 16832603.
35. Kummar S, Gutierrez ME, Gardner ER, Chen X, Figg WD, Zajac-Kaye M, Chen M, Steinberg SM, Muir CA, Yancey MA, et al. Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies. Eur J Cancer 2010, 46:340-347. 10.1016/j.ejca.2009.10.026, 2818572, 19945858.
36. Heath EI, Hillman DW, Vaishampayan U, Sheng S, Sarkar F, Harper F, Gaskins M, Pitot HC, Tan W, Ivy SP, et al. A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. Clin Cancer Res 2008, 14:7940-7946. 10.1158/1078-0432.CCR-08-0221, 3085545, 19047126.
37. Huang KH, Veal JM, Fadden RP, Rice JW, Eaves J, Strachan JP, Barabasz AF, Foley BE, Barta TE, Ma W, et al. Discovery of novel 2-aminobenzamide inhibitors of heat shock protein 90 as potent, selective and orally active antitumor agents. J Med Chem 2009, 52:4288-4305. 10.1021/jm900230j, 19552433.
38. Okawa Y, Hideshima T, Steed P, Vallet S, Hall S, Huang K, Rice J, Barabasz A, Foley B, Ikeda H, et al. SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK. Blood 2009, 113:846-855. 10.1182/blood-2008-04-151928, 2630270, 18948577.
39. Breinig M, Caldas-Lopes E, Goeppert B, Malz M, Rieker R, Bergmann F, Schirmacher P, Mayer M, Chiosis G, Kern MA. Targeting heat shock protein 90 with non-quinone inhibitors: a novel chemotherapeutic approach in human hepatocellular carcinoma. Hepatology 2009, 50:102-112. 10.1002/hep.22912, 19441108.
40. Chiosis G, Lucas B, Huezo H, Solit D, Basso A, Rosen N. Development of purine-scaffold small molecule inhibitors of Hsp90. Curr Cancer Drug Targets 2003, 3:371-376. 10.2174/1568009033481778, 14529388.
41. Taldone T, Gozman A, Maharaj R, Chiosis G. Targeting Hsp90: small-molecule inhibitors and their clinical development. Curr Opin Pharmacol 2008, 8:370-374. 10.1016/j.coph.2008.06.015, 2760289, 18644253.
42. Bali P, Pranpat M, Bradner J, Balasis M, Fiskus W, Guo F, Rocha K, Kumaraswamy S, Boyapalle S, Atadja P, et al. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem 2005, 280:26729-26734. 10.1074/jbc.C500186200, 15937340.
43. Kovacs JJ, Murphy PJ, Gaillard S, Zhao X, Wu JT, Nicchitta CV, Yoshida M, Toft DO, Pratt WB, Yao TP. HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol Cell 2005, 18:601-607. 10.1016/j.molcel.2005.04.021, 15916966.
44. Scroggins BT, Robzyk K, Wang D, Marcu MG, Tsutsumi S, Beebe K, Cotter RJ, Felts S, Toft D, Karnitz L, et al. An acetylation site in the middle domain of hsp90 regulates chaperone function. Mol Cell 2007, 25:151-159. 10.1016/j.molcel.2006.12.008, 1839984, 17218278.
45. Mie Lee Y, Kim SH, Kim HS, Jin Son M, Nakajima H, Jeong Kwon H, Kim KW. Inhibition of hypoxia-induced angiogenesis by FK228, a specific histone deacetylase inhibitor, via suppression of HIF-1alpha activity. Biochem Biophys Res Commun 2003, 300:241-246. 10.1016/S0006-291X(02)02787-0, 12480550.
46. Kekatpure VD, Dannenberg AJ, Subbaramaiah K. HDAC6 modulates HSP90 chaperone activity and regulates activation of aryl hydrocarbon receptor signaling. J Biol Chem 2009,
47. Fiskus W, Ren Y, Mohapatra A, Bali P, Mandawat A, Rao R, Herger B, Yang Y, Atadja P, Wu J, Bhalla K. Hydroxamic acid analogue histone deacetylase inhibitors attenuate estrogen receptor-alpha levels and transcriptional activity: a result of hyperacetylation and inhibition of chaperone function of heat shock protein 90. Clin Cancer Res 2007, 13:4882-4890. 10.1158/1078-0432.CCR-06-3093, 17699868.
48. Qian DZ, Kachhap SK, Collis SJ, Verheul HM, Carducci MA, Atadja P, Pili R. Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1 alpha. Cancer Res 2006, 66:8814-8821. 10.1158/0008-5472.CAN-05-4598, 16951198.
49. Liang D, Kong X, Sang N. Effects of histone deacetylase inhibitors on HIF-1. Cell Cycle 2006, 5:2430-2435. 10.4161/cc.5.21.3409, 17102633.
50. Kong X, Lin Z, Liang D, Fath D, Sang N, Caro J. Histone deacetylase inhibitors induce VHL and ubiquitin-independent proteasomal degradation of hypoxia-inducible factor 1alpha. Mol Cell Biol 2006, 26:2019-2028. 10.1128/MCB.26.6.2019-2028.2006, 1430285, 16507982.
51. Lundgren K, Zhang H, Brekken J, Huser N, Powell RE, Timple N, Busch DJ, Neely L, Sensintaffar JL, Yang YC, et al. BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90. Mol Cancer Ther 2009, 8:921-929. 10.1158/1535-7163.MCT-08-0758, 19372565.
52. Yun TJ, Harning EK, Giza K, Rabah D, Li P, Arndt JW, Luchetti D, Biamonte MA, Shi J, Lundgren K, et al. EC144, a synthetic inhibitor of heat shock protein 90, blocks innate and adaptive immune responses in models of inflammation and autoimmunity. J Immunol 2011, 186:563-575. 10.4049/jimmunol.1000222, 21131419.
53. Tiruppathi C, Malik AB, Del Vecchio PJ, Keese CR, Giaever I. Electrical method for detection of endothelial cell shape change in real time: assessment of endothelial barrier function. Proc Natl Acad Sci USA 1992, 89:7919-7923. 10.1073/pnas.89.17.7919, 49826, 1518814.
54. Sowter HM, Raval RR, Moore JW, Ratcliffe PJ, Harris AL. Predominant role of hypoxia-inducible transcription factor (Hif)-1alpha versus Hif-2alpha in regulation of the transcriptional response to hypoxia. Cancer Res 2003, 63:6130-6134.
55. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER, Ratcliffe PJ. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999, 399:271-275. 10.1038/20459, 10353251.
56. Anelli V, Gault CR, Cheng AB, Obeid LM. Sphingosine kinase 1 is up-regulated during hypoxia in U87MG glioma cells. Role of hypoxia-inducible factors 1 and 2. J Biol Chem 2008, 283:3365-3375.
57. Menrad H, Werno C, Schmid T, Copanaki E, Deller T, Dehne N, Brune B. Roles of hypoxia-inducible factor-1alpha (HIF-1alpha) versus HIF-2alpha in the survival of hepatocellular tumor spheroids. Hepatology 2010, 51:2183-2192. 10.1002/hep.23597, 20513003.
58. Bohensky J, Terkhorn SP, Freeman TA, Adams CS, Garcia JA, Shapiro IM, Srinivas V. Regulation of autophagy in human and murine cartilage: hypoxia-inducible factor 2 suppresses chondrocyte autophagy. Arthritis Rheum 2009, 60:1406-1415. 10.1002/art.24444, 2747039, 19404942.
59. Kaluz S, Kaluzova M, Liao SY, Lerman M, Stanbridge EJ. Transcriptional control of the tumor- and hypoxia-marker carbonic anhydrase 9: A one transcription factor (HIF-1) show?. Biochim Biophys Acta 2009, 1795:162-172. 2670353, 19344680.
60. Erler JT, Bennewith KL, Nicolau M, Dornhofer N, Kong C, Le QT, Chi JT, Jeffrey SS, Giaccia AJ. Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 2006, 440:1222-1226. 10.1038/nature04695, 16642001.
61. Mizukami Y, Kohgo Y, Chung DC. Hypoxia inducible factor-1 independent pathways in tumor angiogenesis. Clin Cancer Res 2007, 13:5670-5674. 10.1158/1078-0432.CCR-07-0111, 17908955.
62. Robey IF, Stephen RM, Brown KS, Baggett BK, Gatenby RA, Gillies RJ. Regulation of the Warburg effect in early-passage breast cancer cells. Neoplasia 2008, 10:745-756. 2481565, 18670636.
63. Zhang X, Gaspard JP, Chung DC. Regulation of vascular endothelial growth factor by the Wnt and K-ras pathways in colonic neoplasia. Cancer Res 2001, 61:6050-6054.
64. Semenza GL. HIF-1: using two hands to flip the angiogenic switch. Cancer Metastasis Rev 2000, 19:59-65. 10.1023/A:1026544214667, 11191064.
65. Bohonowych JE, Gopal U, Isaacs JS. Hsp90 as a gatekeeper of tumor angiogenesis: clinical promise and potential pitfalls. J Oncol 2010, 2010:412985. 2902748, 20628489.
66. Isaacs JS, Jung YJ, Neckers L. Aryl hydrocarbon nuclear translocator (ARNT) promotes oxygen-independent stabilization of hypoxia-inducible factor-1alpha by modulating an Hsp90-dependent regulatory pathway. J Biol Chem 2004, 279:16128-16135. 10.1074/jbc.M313342200, 14764593.
67. Qian DZ, Kato Y, Shabbeer S, Wei Y, Verheul HM, Salumbides B, Sanni T, Atadja P, Pili R. Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589. Clin Cancer Res 2006, 12:634-642. 10.1158/1078-0432.CCR-05-1132, 16428510.
68. Tacchini L, Dansi P, Matteucci E, Desiderio MA. Hepatocyte growth factor signalling stimulates hypoxia inducible factor-1 (HIF-1) activity in HepG2 hepatoma cells. Carcinogenesis 2001, 22:1363-1371. 10.1093/carcin/22.9.1363, 11532856.
69. Koga F, Tsutsumi S, Neckers LM. Low dose geldanamycin inhibits hepatocyte growth factor and hypoxia-stimulated invasion of cancer cells. Cell Cycle 2007, 6:1393-1402. 10.4161/cc.6.11.4296, 17525527.
70. Kong D, Li Y, Wang Z, Banerjee S, Sarkar FH. Inhibition of angiogenesis and invasion by 3,3'-diindolylmethane is mediated by the nuclear factor-kappaB downstream target genes MMP-9 and uPA that regulated bioavailability of vascular endothelial growth factor in prostate cancer. Cancer Res 2007, 67:3310-3319. 10.1158/0008-5472.CAN-06-4277, 17409440.
71. Gopal U, Bohonowych JE, Lema-Tome C, Liu A, Garrett-Mayer E, Wang B, Isaacs JS. A novel extracellular Hsp90 mediated co-receptor function for LRP1 regulates EphA2 dependent glioblastoma cell invasion. PLoS One 2011, 6:e17649. 10.1371/journal.pone.0017649, 3050925, 21408136.
72. Andreasen PA, Egelund R, Petersen HH. The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci 2000, 57:25-40. 10.1007/s000180050497, 10949579.
73. Sullivan R, Graham CH. Hypoxia-driven selection of the metastatic phenotype. Cancer Metastasis Rev 2007, 26:319-331. 10.1007/s10555-007-9062-2, 17458507.
74. Xu K, Ding Q, Fang Z, Zheng J, Gao P, Lu Y, Zhang Y. Silencing of HIF-1alpha suppresses tumorigenicity of renal cell carcinoma through induction of apoptosis. Cancer Gene Ther 2010, 17:212-222. 10.1038/cgt.2009.66, 19816521.
75. Xie Q, Gao CF, Shinomiya N, Sausville E, Hay R, Gustafson M, Shen Y, Wenkert D, Vande Woude GF. Geldanamycins exquisitely inhibit HGF/SF-mediated tumor cell invasion. Oncogene 2005, 24:3697-3707. 10.1038/sj.onc.1208499, 15782129.
76. Kim LC, Song L, Haura EB. Src kinases as therapeutic targets for cancer. Nat Rev Clin Oncol 2009, 6:587-595. 10.1038/nrclinonc.2009.129, 19787002.
77. Hauck CR, Hsia DA, Schlaepfer DD. The focal adhesion kinase--a regulator of cell migration and invasion. IUBMB Life 2002, 53:115-119. 10.1080/15216540211470, 12049193.
78. Yano A, Tsutsumi S, Soga S, Lee MJ, Trepel J, Osada H, Neckers L. Inhibition of Hsp90 activates osteoclast c-Src signaling and promotes growth of prostate carcinoma cells in bone. Proc Natl Acad Sci USA 2008, 105:15541-15546. 10.1073/pnas.0805354105, 2563126, 18840695.
79. Tang CH, Wei Y. The urokinase receptor and integrins in cancer progression. Cell Mol Life Sci 2008, 65:1916-1932. 10.1007/s00018-008-7573-9, 18345479.
80. Palazzo A, Ackerman B, Gundersen GG. Cell biology: tubulin acetylation and cell motility. Nature 2003, 421:230.
81. Regan PL, Jacobs J, Wang G, Torres J, Edo R, Friedmann J, Tang XX. Hsp90 inhibition increases p53 expression and destabilizes MYCN and MYC in neuroblastoma. Int J Oncol 2011, 38:105-112. 3212671, 21109931.
82. Padua D, Zhang XH, Wang Q, Nadal C, Gerald WL, Gomis RR, Massague J. TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell 2008, 133:66-77. 10.1016/j.cell.2008.01.046, 2390892, 18394990.
83. Nagy JA, Benjamin L, Zeng H, Dvorak AM, Dvorak HF. Vascular permeability, vascular hyperpermeability and angiogenesis. Angiogenesis 2008, 11:109-119. 10.1007/s10456-008-9099-z, 2480489, 18293091.
84. Chatterjee A, Snead C, Yetik-Anacak G, Antonova G, Zeng J, Catravas JD. Heat shock protein 90 inhibitors attenuate LPS-induced endothelial hyperpermeability. Am J Physiol Lung Cell Mol Physiol 2008, 294:L755-763. 10.1152/ajplung.00350.2007, 18245267.
85. Antonov A, Snead C, Gorshkov B, Antonova GN, Verin AD, Catravas JD. Heat shock protein 90 inhibitors protect and restore pulmonary endothelial barrier function. Am J Respir Cell Mol Biol 2008, 39:551-559. 10.1165/rcmb.2007-0324OC, 2574526, 18474672.
86. Chen L, Uchida K, Endler A, Shibasaki F. Mammalian tumor suppressor Int6 specifically targets hypoxia inducible factor 2 alpha for degradation by hypoxia- and pVHL-independent regulation. J Biol Chem 2007, 282:12707-12716. 10.1074/jbc.M700423200, 17324924.
87. Koh MY, Darnay BG, Powis G. Hypoxia-associated factor, a novel E3-ubiquitin ligase, binds and ubiquitinates hypoxia-inducible factor 1alpha, leading to its oxygen-independent degradation. Mol Cell Biol 2008, 28:7081-7095. 10.1128/MCB.00773-08, 2593390, 18838541.
88. Fath DM, Kong X, Liang D, Lin Z, Chou A, Jiang Y, Fang J, Caro J, Sang N. Histone deacetylase inhibitors repress the transactivation potential of hypoxia-inducible factors independently of direct acetylation of HIF-alpha. J Biol Chem 2006, 281:13612-13619. 10.1074/jbc.M600456200, 1564196, 16543236.
89. Bendinelli P, Matteucci E, Maroni P, Desiderio MA. NF-kappaB activation, dependent on acetylation/deacetylation, contributes to HIF-1 activity and migration of bone metastatic breast carcinoma cells. Mol Cancer Res 2009, 7:1328-1341. 10.1158/1541-7786.MCR-08-0548, 19671685.
90. Kim SH, Jeong JW, Park JA, Lee JW, Seo JH, Jung BK, Bae MK, Kim KW. Regulation of the HIF-1alpha stability by histone deacetylases. Oncol Rep 2007, 17:647-651.
91. Saito S, Lasky JA, Guo W, Nguyen H, Mai A, Danchuk S, Sullivan DE, Shan B. Pharmacological inhibition of HDAC6 attenuates endothelial barrier dysfunction induced by thrombin. Biochem Biophys Res Commun 2011,
92. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005, 307:58-62. 10.1126/science.1104819, 15637262.
93. Niu G, Li Z, Cao Q, Chen X. Monitoring therapeutic response of human ovarian cancer to 17-DMAG by noninvasive PET imaging with (64) Cu-DOTA-trastuzumab. Eur J Nucl Med Mol Imaging 2009, 36:1510-1519. 10.1007/s00259-009-1158-1, 19440708.
94. Chandarlapaty S, Scaltriti M, Angelini P, Ye Q, Guzman M, Hudis CA, Norton L, Solit DB, Arribas J, Baselga J, Rosen N. Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth. Oncogene 2010, 29:325-334. 10.1038/onc.2009.337, 3057066, 19855434.
95. Smith-Jones PM, Solit D, Afroze F, Rosen N, Larson SM. Early tumor response to Hsp90 therapy using HER2 PET: comparison with 18 F-FDG PET. J Nucl Med 2006, 47:793-796. 3193602, 16644749.
96. Smith-Jones PM, Solit DB, Akhurst T, Afroze F, Rosen N, Larson SM. Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors. Nat Biotechnol 2004, 22:701-706. 10.1038/nbt968, 15133471.
97. Niu G, Cai W, Chen K, Chen X. Non-invasive PET imaging of EGFR degradation induced by a heat shock protein 90 inhibitor. Mol Imaging Biol 2008, 10:99-106. 10.1007/s11307-007-0123-2, 18157579.
98. Kim YS, Alarcon SV, Lee S, Lee MJ, Giaccone G, Neckers L, Trepel JB. Update on Hsp90 inhibitors in clinical trial. Curr Top Med Chem 2009, 9:1479-1492. 10.2174/156802609789895728, 19860730.